As COVID-19 patients run the risk of bacterial coinfections & adverse outcome…Ortho Clinical Diagnostics targets sepsis threat with its VITROS B•R•A•H•M•S PCT assay
In the wake of COVID-19, it has been observed that the clinical course of adult inpatients may include sepsis, acute cardiac injury or acute kidney injury among others. Biochemical monitoring of COVID-19 patients through in vitro diagnostic testing is critical for assessing disease severity and progression as well as monitoring therapeutic intervention.
VITROS® B•R•A•H•M•S PCT (Procalcitonin) Assay has been recently launched by Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, in India. VITROS® B•R•A•H•M•S PCT (Procalcitonin) assay can help clinicians for the early detection and differential diagnosis of clinically relevant bacterial infections; the assessment of the degree of severity and the prognosis of the outcome of systemic bacterial infection, sepsis, severe sepsis and septic shock and in antibiotic stewardship program in the treatment process. Ortho’s newest assay is available on the VITROS® 3600 Immunodiagnostic System, VITROS® 5600 and VITROS® XT 7600 Integrated Systems and VITROS® ECi/ECiQ Systems.
Dangers of Sepsis among COVID-19 Patients
· Sepsis is a life-threatening clinical condition caused by the body’s extreme response to infection.
· If unrecognized or untreated, it can lead to systemic inflammation, tissue damage and organ failure or death.
· Sepsis is estimated to affect more than 30 million people globally each year, potentially leading to six million deaths.
· Sepsis was the most frequently identified complication among COVID-19 patients followed by respiratory failure, ARDS, Heart failure and Septic shock, resulting in mortality.
How VITROS® B•R•A•H•M•S PCT helps
The VITROS® B•R•A•H•M•S PCT assay can aid clinical assessment in the early detection of severe bacterial infections (sepsis, community-acquired pneumonia, acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease) and in making decisions regarding antibiotic therapy. Emerging antibiotic resistance has made it extremely important to reduce the unnecessary and prolonged use of antibiotics.
Ortho Clinical Diagnostics has also recently introduced two COVID-19 Antibody Tests with 100% specificity that helps to identify previously exposed individuals, who have developed antibodies to SARS-CoV-2 (COVID-19 virus).
“Because Every Test Is a Life, Ortho Clinical Diagnostics is committed to providing medical teams with high-quality diagnostics that deliver accurate results that help clinicians treat their patients faster.” - Ravi Sinha, Country Director- India / Other SAARC Countries, Ortho Clinical Diagnostics
BACKGROUNDER
VITROS edge in labs
Laboratories running the NEW VITROS B•R•A•H•M•S PCT assay leverage both the power of B•R•A•H•M•S and the technical superiority with enabling technologies that only VITROS® analyzers can provide.
Paired together, these VITROS® Solutions help improve patient outcomes by delivering consistently Fast, Accurate and Reliable results to the clinicians which supports better diagnosis, treatment, monitoring and disease management. Given this VITROS benefit, labs can fulfill more requests from difficult draws with the assay’s small sample size at 30μL. Also,
· VITROS technology ensures results are ready to be delivered to clinicians quickly, with a 96.5% first pass yield (without user intervention).
· Proprietary MicroSensor™ technology detects and flags results with potential hemolysis, icterus and turbidity interferences, reducing the need for reviews/reruns/redraws.
· With a guaranteed uptime of 98%, these solutions improve a lab’s ability to deliver better patient outcomes.
Self-contained, waterless VITROS® Systems help ensure results are not impacted by water quality and go hand-in-hand with Ortho’s goal to support long-term environmental sustainability.
Ortho’s 100% specificity-compliant methodology
§ Being 100% specificity-compliant, Ortho’s VITROS® Anti-SARS-CoV-2 Total and IgG tests can help to identify, with great confidence, previously exposed individuals who have developed antibodies to SARS-CoV-2.
§ When coupled with information from a molecular test that detects active infection, it can monitor the progression of the disease by measuring when antibodies appear in the blood.
About Ortho Clinical Diagnostics
§ Ortho Clinical Diagnostics is a global leader of in vitro diagnostics, dedicated to saving and improving lives through innovative laboratory testing and blood-typing solutions- for the past 3 decades.
§ It has a strong legacy of infectious marker leadership.
§ Ortho’s products have been approved by the US FDA & CE Marked.
§ Because Every Test is a Life™, Ortho never stops innovating to offer streamlined, sustainable laboratory solutions that deliver fast, accurate and reliable test results that support exceptional patient care
§ Ortho is powered by Ortho Care™, its global, award-winning, holistic approach to service, which supports customers with best-in-class technical support and award-winning field support, besides remote service and inventory support.
‘Saving lives, saving economy’
‘The COVID-19 pandemic continues to impact individuals, communities and families around the world. Ortho is proud to be working towards large-scale solutions that will help people return to work, reducing the strain on both employees and the economy as a whole. Our focus on improving patients’ lives through diagnostics led us to developing this test rapidly, providing one of the key resources needed for diagnosing and treating Covid-19. We remain committed to helping laboratories deliver faster and more accurate and reliable results to healthcare professionals, patients and researchers developing long-term, sustainable management of this disease.’
— Chris Smith, Chief Executive Officer, Ortho Clinical Diagnostics, USA
‘75-year track record’
‘Our test kits have been approved by the CE and the FDA (EUA). They are widely used by prestigious hospitals and labs, such as Mayo Clinic in the US. Our instruments are used for HIV, HBsAg and HCV screening across the world and the technology is being used for blood screening for more than 25 years in prestigious hospitals and blood banks in India and other SAARC countries. The process control audit trail for each step of analysis is available to provide confidence in reporting.’
— Anand Pande, Vice-President- Asia-Pacific Region, Ortho Clinical Diagnostics
